

Treatment of Melanoma

Reference Number: F4583
Date of Response: 17th May 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Request and Royal Devon and Exeter NHS Foundation Trust Response

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

- Bevacizumab (Avastin) – **0 Patients**
- Dacarbazine (DTIC) – **0 Patients**
- Trametinib (Mekinist) – **11 Patients**
- Dabrafenib (Tafinlar) – **12 Patients**
- Vemurafenib (Zelboraf) – **0 Patients**
- Nivolumab (Opdivo) – **11 Patients**
- Nivolumab + Ipilimumab (Opdivo + Yervoy) – **0 Patients**
- Pembrolizumab (Keytruda) – **38 Patients**
- Vemurafenib + cobimetinib (Zelboraf + Cotellic) – **0 Patients**
- Dabrafenib + Trametinib (Tafinlar + Mekinist) – **11 Patients**

In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:

- **Ipilimumab (Yervoy)**
- **Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 Patients**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. therefore this would breach Caldicott principles and principle One of the GDPR.

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

- Ipilimumab AND Nivolumab – **0 Patients**
- Nivolumab – **11 Patients**
- Pembrolizumab – **12 Patients**
- Dabrafenib AND Trametinib – **8 Patients**
 - Trametinib – **0 patients**
 - Vemurafenib – **0 patients**
 - Vemurafenib AND Cobimetinib – **0 patients**

In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:

- **Ipilimumab**
- **Any Other Targeted Therapy**
- **Dabrafenib**
- **Encorafenib AND Binimetinib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. therefore this would breach Caldicott principles and principle One of the GDPR.